Serious infection risk in children with psoriasis on systemic treatment: a propensity score matched population-based study.

Like Comment
Psoriasis (PsO) is increasingly treated with systemic medications, yet their safety is not well characterized in children.We sought to estimate the 6-month risk of serious infections in children with PsO treated with biologics, systemic non-biologics and phototherapy.Using insurance claims data, we identified children <18 years with PsO and compared the frequency of serious infections in those initiating biologics, systemic non-biologics, and phototherapy. Relative risks (RR) were estimated before and after 1:1 propensity-score matching.Among 57,323 children with PsO, the 6-month risk of infection was 4.2 per 1,000 patient-years in 722 biologic initiators, 5.1 in 988 systemic non-biologic initiators, and 1.1 in 2,657 phototherapy initiators. The RR of infection in biologics vs. non-biologics was 0.67 (0.11, 3.98), in biologics vs. phototherapy was 1.50 (0.25, 8.95) and in non-biologics vs. phototherapy was 5.00 (0.59, 42.71). The background risk of infection in children with PsO was 1 per 1,000, almost double the risk compared to children without PsO (RR=1.84; 1.15, 1.97).We found no meaningful difference in infection risk between biologics vs. non-biologics, and no robust difference between systemic users vs. phototherapy. Independent of treatment, children with PsO had a higher risk of infection than those without PsO.


Click here to read the full article @ Journal of the American Academy of Dermatology
Go to the profile of ClinOwl

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2311 Contributions
1 Followers
0 Following

No comments yet.